Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic
breast cancer. The dose used in studies so far has been well tolerated and may be too low for
optimal effectiveness. In this study, a higher dose will be used to see whether an improved
outcome will result.
Phase:
Phase 2
Details
Lead Sponsor:
Beth Israel Deaconess Medical Center
Collaborators:
Brigham and Women's Hospital Dana-Farber Cancer Institute Lowell General Hospital Massachusetts General Hospital South Shore Hospital University of Colorado, Denver University of Maryland Greenebaum Cancer Center